The key to treating rare diseases is not just CRISPR technology but a regulatory shift toward an "umbrella" or "platform" strategy. This allows multiple drugs for different mutations to be tested under a single trial, drastically lowering costs and making it feasible to develop treatments for tiny patient populations.
As large AI models absorb functions of traditional SaaS products, investors and entrepreneurs are shifting focus back to tech-enabled services. Integrating AI deeply into physical services and workflows is now seen as creating more defensible, lasting value than pure software, reversing a years-long trend.
In a fast-moving AI landscape, startups can create defensible moats by leveraging new tools to rapidly build solutions for highly specific customer needs. This deep personalization—for a niche provider, rare disease patient, or specific administrative workflow—creates a "wow moment" that large, generalist models struggle to replicate.
After a year of extensive experimentation, major pharmaceutical companies are now adopting AI at scale, marked by large-scale deals with AI tooling companies. This signals a market inflection point where pharma is moving beyond testing and is actively deploying AI across R&D and commercial functions after seeing demonstrable ROI.